Eczema

San Antonio, TX

49 Eczema Trials near San Antonio, TX

Power is an online platform that helps thousands of Eczema patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization. The primary safety objective of this study is to compare the safety profile of ShA9 to placebo (vehicle) over 14 weeks of application, which includes an initial two-week period of co-treatment with topical corticosteroids (TCS). The primary efficacy objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with TCS.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+

86 Participants Needed

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

79 Participants Needed

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

163 Participants Needed

Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

24 Participants Needed

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

204 Participants Needed

Rocatinlimab for Eczema

Corpus Christi, Texas
This trial tests the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe atopic dermatitis. Rocatinlimab works by reducing inflammation and calming the immune system.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 17

187 Participants Needed

This trial tests a modified protein called rezpegaldesleukin in adults with moderate to severe atopic dermatitis. The treatment aims to help the immune system reduce skin inflammation and symptoms.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

396 Participants Needed

Barzolvolimab for Eczema

Sugar Land, Texas
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

120 Participants Needed

Lebrikizumab for Eczema

Sugar Land, Texas
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:12+

120 Participants Needed

Amlitelimab for Eczema

Missouri City, Texas
This trial is testing amlitelimab, a medication for adults with moderate to severe atopic dermatitis who were in a previous trial. The study aims to see if the medication is safe and effective over an extended time. Amlitelimab works by calming the immune system to reduce skin inflammation.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:12+

1551 Participants Needed

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

62 Participants Needed

Rocatinlimab for Eczema

The Woodlands, Texas
This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

769 Participants Needed

This trial is testing a new medication called eblasakimab for people with moderate-to-severe atopic dermatitis who have already tried another treatment called dupilumab. The medication aims to reduce skin inflammation and improve symptoms. The study will last for several months, including a treatment period and a follow-up.

Trial Details

Trial Status:Recruiting

75 Participants Needed

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 2

100 Participants Needed

This trial is testing a skin cream called ruxolitinib to see if it can help people with Atopic Dermatitis sleep better by reducing inflammation and itching. Ruxolitinib cream is used to treat inflammatory skin diseases like atopic dermatitis.
No Placebo Group

Trial Details

Trial Status:Recruiting

100 Participants Needed

SuperSite
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+

249 Participants Needed

IMG-007 for Eczema

Southlake, Texas
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

220 Participants Needed

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

225 Participants Needed

OpSCF for Eczema

Frisco, Texas
This trial is testing a new medicine called OpSCF for adults with moderate to severe eczema. OpSCF works by blocking proteins that cause skin inflammation. The study will evaluate if OpSCF is effective and safe.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

48 Participants Needed

Why Other Patients Applied

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Know someone looking for new options? Spread the word